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We	identified	3	lineages	among	multidrug-resistant	(MDR)	
Salmonella enterica	 serotype	Typhi	 isolates	 in	 the	Gulf	of	
Guinea	 region	 in	 Africa	 during	 the	 2000s.	 However,	 the	
MDR	H58	haplotype,	which	predominates	in	southern	Asia	
and	Kenya,	was	not	identified.	MDR	quinolone-susceptible	
isolates	contained	a	190-kb	incHI1	pST2	plasmid	or	a	50-kb	
incN	pST3	plasmid.
Typhoid fever, which is caused by Salmonella enterica serotype Typhi, is endemic to the developing world; 
there were an estimated 26.7 million cases in 2010 (1). 
The incidence of typhoid fever in sub-Saharan Africa was 
an estimated 725 cases/100,000 persons in 2010, despite 
a lack of incidence studies conducted in West and central 
Africa (1). Antimicrobial susceptibility data are also scarce 
for this part of Africa. This issue is problematic because 
treatment with appropriate antimicrobial drugs is essential 
for recovery in the context of the global emergence of mul-
tidrug resistance.
In the Indian subcontinent and Southeast Asia, the 
multidrug-resistant (MDR) Salmonella Typhi H58 clone, 
which was named after its haplotype (a combination of 
defined chromosomal single-nucleotide polymorphisms 
[SNPs]) (2,3), has spread rapidly and become endemic and 
predominant. During the 1990s, this clone acquired a large 
conjugative incHI1 pST6 plasmid encoding resistance to 
ampicillin, chloramphenicol, and co-trimoxazole (4,5); 
also in the 1990s, this MDR clone became resistant to qui-
nolones and showed decreased susceptibility to ciprofloxa-
cin because of point mutations in the chromosomal gyrA 
gene (2). The H58 clone has also spread to eastern Africa, 
where it has been the most prevalent haplotype (87%) in 
Kenya since the early 2000s (6).
During 1997–2011, high incidence of MDR Salmo-
nella Typhi was reported in some countries near the Gulf 
of Guinea in Africa, including Nigeria (7), Ghana (8,9), 
Togo (10), and the Democratic Republic of the Congo (11). 
During 1999–2003, a British surveillance system reported 
a prevalence of 19% (49/421) for MDR Salmonella Typhi 
isolates among imported cases of typhoid fever acquired 
in Africa, particularly in Ghana (12). However, nothing 
is known about the genotypes of these isolates, including 
whether they belong to the spreading MDR H58 clone.
We report data for the occurrence, genotypes, and 
characterization of the resistance mechanisms of MDR 
Salmonella Typhi isolates. These isolates were obtained 
from the French National Reference Center for Salmonella 
(FNRC-Salm), Institut Pasteur (Paris, France), and Centre 
Pasteur du Cameroun (Yaoundé, Cameroon).
The Study
Almost all Salmonella Typhi strains isolated in France are 
referred to the FNRC-Salm. Most isolates were obtained 
from travelers or immigrants, most of whom were infected 
in Africa and Asia. In Cameroon, the Centre Pasteur du 
Cameroun collects Salmonella Typhi isolates from several 
hospitals in.
Antimicrobial susceptibility testing was performed ac-
cording to the guidelines of the antibiogram committee of 
the French Society for Microbiology (http://www.sfm.asso.
fr/nouv/general.php?pa = 2). Isolates were considered to be 
MDR if they were resistant to ≥2 of the following antimi-
crobial drugs: amoxicillin, co-trimoxazole (trimethoprim/
sulfamethoxazole), chloramphenicol, or tetracyclines.
During 1996–2013, a total of 1,746 Salmonella Typhi 
isolates were collected through the French national surveil-
lance system and subjected to antimicrobial susceptibility 
testing; 408 were acquired in sub-Saharan Africa (n = 237) 
and northern Africa (n = 171), and 55 (13.5%) of those ac-
quired in Africa were MDR (Table). All but 1 of the MDR 
isolates were acquired in sub-Saharan Africa (Table). The 
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proportion of MDR isolates increased from 0% during 
1996–1999 to 22.3% (n = 23) during 2010–2013. Only 4 
isolates from Africa were resistant to nalidixic acid, includ-
ing 1 isolate resistant to ciprofloxacin. Because these iso-
lates acquired after 2010 were not MDR isolates, they were 
not studied further.
In Yaoundé, the proportion of MDR isolates was high 
(45.5 %, 29/61) in the first survey during 2000–2004. How-
ever, this proportion increased to 75.5% (37/49) during 
2010–2013.
We studied 61 isolates (online Technical Appendix, 
http://wwwnc.cd.gov/EID/article/21/3/14-1355-Techapp1.
xlsx). Of these, 46 were MDR: 29 acquired in Africa and 
detected at FNRC-Salm before 2010; 2 acquired in France 
during 2009 at an African festive meal (13); 12 randomly 
selected acquired in Yaoundé during 2002–2007; 2 ac-
quired in the Central African Republic, and 1 acquired 
in Morocco (2). The remaining 15 comparison strains 
(MDR or drug susceptible) that belonged to various hap-
lotypes and were acquired in Africa and Asia during 
1958–2009.
Mechanisms of antimicrobial drug resistance were 
determined as described (14). Genetic diversity and phy-
logenetic relationships were studied by using standardized 
XbaI–pulsed-field gel electrophoresis (PFGE) (http://www.
cdc.gov/pulsenet/pathogens/index.html), haplotyping (5), 
and clustered regularly interspaced short palindromic re-
peats (CRISPR) typing (15). Haplotyping was based on 
identification of SNPs at 1,487 defined chromosomal loci, 
and CRISPR typing was based on detection of 32-bp se-
quences (spacers) within 1 or both CRISPR regions.
With the exception of the isolate from Morocco (ISP-
03-07467) (2), none of the isolates had the H58 haplotype 
or contained the associated incHI1 pST6 MDR plasmid. 
We found 3 other lineages with different geographic distri-
butions and MDR plasmids (Figures 1, 2).
Lineage A consisted mostly of haplotype H56 isolates 
and more rarely H42 (which differs from H56 by 2 SNPs) 
and was found only in the western part of the Gulf of Guin-
ea region. Lineage B consisted of haplotype H55 isolates 
and was found in the eastern and southern parts of the Gulf 
of Guinea region. Lineage C consisted of haplotype H77 
isolates and was found only in Cameroon. All 3 lineages 
had distinctive CRISPR1 spacer contents. XbaI-PFGE, 
which used a similarity value of ≥90% as a cutoff, correctly 
grouped (i.e., concordant with haplotyping and CRISPR re-
sults) all but 2 of the MDR isolates from Africa (Figure 1; 
online Technical Appendix).
The 3 lineages contained a large (≈190 kb) conjugative 
MDR incHI1 pST2 plasmid that differed among lineages. 
Resistance to trimethoprim was encoded by different class 
1 integron gene cassettes: dfrA15, dfrA7, and dfrA1 for in-
cHI1 plasmids of lineages A, B, and C, respectively. All in-
cHI1 plasmids from lineage A encoded resistance to chlor-
amphenicol, and none of those from lineage C encoded 
such resistance. A second smaller (50-kb) MDR plasmid 
belonging to the incN incompatibility group (pST3 by plas-
mid multilocus sequence typing), was present mostly in lin-
eage C isolates, but was also found in 1 lineage A isolate 
(02-1739) (online Technical Appendix).
Conclusions
Analysis of older isolates and previously published data (2) 
showed that susceptible Salmonella Typhi strains of hap-
lotypes H42, H56, and H77 had already been identified in 
Senegal in 1962, Tunisia in 1969, and Cameroon in 1958, 
respectively. This finding suggests that the MDR isolates 
from lineages A and C are derived from local Salmonella 
Typhi populations in Africa, rather than being recently im-
ported from other regions to which this bacterium is en-
demic. Haplotype H55 was previously restricted largely 
to the Indian subcontinent and eastern Africa (2); it was 
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Table. Characteristics	of	Salmonella enterica serotype	Typhi	isolates,	France	and	Cameroon,	1996–2013* 
Location 1996–1999 2000–2004 2005–2009 2010–2013 
France     
 No.	isolates	studied 345 266 627 508 
 No.	isolates	acquired	in	Africa 86 64 155 103 
 No.	(%)	MDR† 0 7	(10.9) 25	(16.1) 23	(22.3) 
Country	of	infection	for	MDR	isolates	(no.)  Benin	(3),	Togo	(2),	
Burkina-Faso	(1),	
Cameroon	(1) 
Cameroon	(7),	 
Côte d’Ivoire (4),	 
Burkina-Faso	(3),	 
Angola	(2),	Congo	(1),	Mali	
(1),	Benin	(1),	Nigeria	(1),	
Mauritania	(1),	Togo	(1),	
Central	African	Republic	
(1),	Guinea	(1),	 
not	specified	(1) 
Côte d’Ivoire (7), 
Guinea	(3),	Burkina-
Faso	(3),	Cameroon	(2),	
Congo	(1),	Central	
African	Republic	(1),	
Niger	(1),	Mali	(1),	
Nigeria	(1),	Chad	(1),	
Togo	(1),	Algeria	(1) 
Yaounde,	Cameroon     
 No.	isolates	studied ND 61 75 49 
 No.	(%)	MDR ND 29	(47.5) 50	(66.6) 37	(75.5) 
*MDR,	multidrug	resistant;	ND,	not	determined.	 
†For	isolates	acquired	in	Africa. 
 
MDR	Salmonella Typhi,	Africa
detected in association with an incHI1 pST2 plasmid in In-
dia during the mid-1970s (5). Therefore, lineage B might 
have been was imported into central Africa from eastern 
Africa/southern Asia.
A previous study also reported isolation of an MDR 
clone in the Democratic Republic of the Congo in 2004 that 
was resistant to quinolones, showed decreased susceptibil-
ity to ciprofloxacin, and belonged to the Asian H58 lineage 
(2). Because only a limited number of isolates from central 
Africa were tested in our study, studies of a larger collection 
of isolates might provide more information about bacterial 
genotypes/MDR plasmids circulating in central Africa.
Despite intrinsic limitations of a laboratory surveillance 
system for typhoid fever that is used mostly for travelers 
and immigrants and has the bias of preferential links caused 
by colonial history and choices of tourist destinations, we 
documented emergence of 3 MDR Salmonella Typhi lin-
eages in the Gulf of Guinea area. Two lineages found in 
Guinea and Cameroon were local lineages that acquired 
MDR conjugative plasmids, either a large incHI1 pST2 
plasmid or a smaller incN pST3 plasmid. The H58 lineage, 
which is currently predominant in Asia and eastern Africa, 
was not detected among MDR isolates from West and cen-
tral Africa.
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Figure 1.	Characteristics	of	50	Salmonella enterica	serotype	Typhi	isolates.	The	dendrogram	was	generated	by	using	BioNumerics	
version	6.6	software	(Applied	Maths,	Sint-Martens-Latem,	Belgium)	and	shows	results	of	cluster	analysis	on	the	basis	of	XbaI–
pulsed-field	gel	electrophoresis	(PFGE)	fingerprinting.	Similarity	analysis	was	performed	by	using	the	Dice	coefficient,	and	clustering	
analysis	was	performed	by	using	UPGMA.	CRISPR1,	clustered	regularly	interspaced	short	palindromic	repeats	1;	MDR,	multidrug	
resistant;	AMX,	amoxicillin;	STR,	streptomycin;	SXT,	trimethoprim/sulfamethoxazole;	CHL,	chloramphenicol;	TET,	tetracycline;	SPT,	
spectinomycin;	SSS,	sulfamethoxazole.	Zaire	is	the	former	name	of	the	Democratic	Republic	of	the	Congo.	Plasmid	multilocus	
sequence	typing	(pMLST)	was	performed	as	described	for	incN	http://pubmlst.org/plasmid/)	or	incHI1	(4).	Plasmid	size	was	estimated	by	
using	S1	nuclease	PFGE	(14).	For	isolates	from	Africa,	red	indicates	linage	A,	blue	indicates	lineage	B,	and	green	indicates	lineage	C.
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